STERIS agrees to acquire Xodus Medical for $2.1bn
STERIS agreed to purchase Pennsylvania-based surgical products maker Xodus Medical for $2.1bn, with closing targeted for 31 December 2026 subject to approvals. Xodus is projected to generate about $245m of 2026 revenue and roughly $135m of adjusted EBIT. STERIS expects cash tax benefits worth roughly $300m in net present value, reducing the effective purchase price to approximately $1.8bn, while potential earnout payments could reach $150m based on calendar 2028 performance.
Why it matters
The acquisition is expected to be financed mainly with debt, adding borrowing exposure for STERIS while expanding its operating-room consumables business. STERIS plans to issue a revised fiscal 2027 outlook incorporating Xodus only after the transaction closes, so near-term guidance remains based on the standalone company.
Key facts
- 1The transaction includes potential earnout consideration of up to $150m tied to performance targets in calendar 2028. financial-news.co.uk
- 2STERIS estimates cash tax benefits with a net present value of roughly $300m, lowering the purchase price to approximately $1.8bn. financial-news.co.uk
- 3Xodus is projected to produce about $245m of 2026 revenue and roughly $135m of adjusted EBIT. financial-news.co.uk
- 4The acquisition is expected to close by 31 December 2026 and is financed mainly with debt. financial-news.co.uk
Open questions
- The claim that the acquisition is accretive appears in material 4, but the materials do not provide quantified accretion figures.
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.